Payment overview · 2025
General Payments
$266.76
6 reported records · 5 companies
Healthcare provider profile · identity verified
John Christopher Wohar, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine · PITTSBURGH, PA · NPI 1578794244
Verified facts
What the public records show
CMS Open Payments records show John Christopher Wohar, D.O. received $266.76 in general payments during 2025 across 6 reported records.
Phathom Pharmaceuticals, Inc. accounted for 52.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Paxlovid.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 219 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $140.36 | 52.6% | 2 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $60.77 | 22.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $25.00 | 9.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $24.89 | 9.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.74 | 5.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $205.99 | 5 |
| Debt forgiveness | $60.77 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $140.36 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $24.89 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.74 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $15.74 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 60 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 38 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
113 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
60 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
219 | 43 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
38 | 37 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 745 | 153 |
| Atorvastatin Calcium | Atorvastatin Calcium | 617 | 156 |
| Lisinopril | Lisinopril | 594 | 143 |
| Amlodipine Besylate | Amlodipine Besylate | 571 | 129 |
| Omeprazole | Omeprazole | 495 | 121 |
| Simvastatin | Simvastatin | 412 | 97 |
| Gabapentin | Gabapentin | 381 | 93 |
| Furosemide | Furosemide | 375 | 107 |
| Losartan Potassium | Losartan Potassium | 329 | 80 |
| Metoprolol Tartrate | Metoprolol Tartrate | 303 | 77 |
| Tamsulosin Hcl | Tamsulosin Hcl | 275 | 71 |
| Hydrochlorothiazide | Hydrochlorothiazide | 271 | 66 |
| Potassium Chloride | Potassium Chloride | 263 | 64 |
| Lorazepam | Lorazepam | 261 | 55 |
| Pantoprazole Sodium | Pantoprazole Sodium | 259 | 65 |
| Metformin Hcl | Metformin Hcl | 255 | 67 |
| Carvedilol | Carvedilol | 243 | 50 |
| Alendronate Sodium | Alendronate Sodium | 231 | 48 |
| Eliquis | Apixaban | 219 | 43 |
| Glipizide | Glipizide | 214 | 41 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 208 | 63 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 199 | 43 |
| Sertraline Hcl | Sertraline Hcl | 197 | 45 |
| Allopurinol | Allopurinol | 176 | 37 |
| Fluticasone Propionate | Fluticasone Propionate | 175 | 68 |
| Prednisone | Prednisone | 174 | 119 |
| Famotidine | Famotidine | 166 | 41 |
| Metoprolol Succinate | Metoprolol Succinate | 165 | 47 |
| Pravastatin Sodium | Pravastatin Sodium | 163 | 40 |
| Duloxetine Hcl | Duloxetine Hcl | 160 | 30 |
| Tramadol Hcl | Tramadol Hcl | 155 | 51 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 154 | 62 |
| Alprazolam | Alprazolam | 149 | 32 |
| Xarelto | Rivaroxaban | 144 | 24 |
| Montelukast Sodium | Montelukast Sodium | 132 | 34 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 131 | 44 |
| Atenolol | Atenolol | 123 | 28 |
| Trazodone Hcl | Trazodone Hcl | 119 | 29 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 117 | 24 |
| Jardiance | Empagliflozin | 113 | 23 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 111 | 23 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 111 | 27 |
| Synthroid | Levothyroxine Sodium | 108 | 25 |
| Meloxicam | Meloxicam | 107 | 30 |
| Warfarin Sodium | Warfarin Sodium | 100 | 26 |
| Fluoxetine Hcl | Fluoxetine Hcl | 98 | 18 |
| Ondansetron Odt | Ondansetron | 98 | 33 |
| Zolpidem Tartrate | Zolpidem Tartrate | 97 | 16 |
| Januvia | Sitagliptin Phosphate | 96 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 95 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 93 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 92 | 21 |
| Irbesartan | Irbesartan | 92 | 21 |
| Spironolactone | Spironolactone | 92 | 24 |
| Buspirone Hcl | Buspirone Hcl | 87 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 87 | 16 |
| Meclizine Hcl | Meclizine Hcl | 84 | 28 |
| Baclofen | Baclofen | 83 | 21 |
| Doxycycline Hyclate | Doxycycline Hyclate | 83 | 39 |
| Celecoxib | Celecoxib | 82 | 19 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 79 | 24 |
| Bupropion Hcl Sr | Bupropion Hcl | 77 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 75 | 15 |
| Oxycodone Hcl | Oxycodone Hcl | 74 | 24 |
| Donepezil Hcl | Donepezil Hcl | 72 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 71 | 16 |
| Ibuprofen | Ibuprofen | 71 | 20 |
| Myrbetriq | Mirabegron | 69 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 68 | 18 |
| Paroxetine Hcl | Paroxetine Hcl | 68 | 18 |
| Breo Ellipta | Fluticasone/Vilanterol | 67 | 15 |
| Metformin Hcl Er | Metformin Hcl | 66 | 19 |
| Valsartan | Valsartan | 63 | 20 |
| Clonazepam | Clonazepam | 61 | 11 |
| Ezetimibe | Ezetimibe | 61 | 14 |
| Ozempic | Semaglutide | 60 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 59 | 12 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 58 | 58 |
| Cefuroxime | Cefuroxime Axetil | 58 | 50 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 53 | 50 |
| Clonidine Hcl | Clonidine Hcl | 53 | suppressed |
| Finasteride | Finasteride | 52 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 50 | suppressed |
| Tradjenta | Linagliptin | 50 | suppressed |
| Pregabalin | Pregabalin | 49 | suppressed |
| Nifedipine Er | Nifedipine | 46 | 11 |
| Valacyclovir | Valacyclovir Hcl | 46 | 24 |
| Glimepiride | Glimepiride | 45 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 42 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 42 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 42 | 21 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 40 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 40 | 11 |
| Levetiracetam | Levetiracetam | 40 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 39 | 12 |
| Memantine Hcl | Memantine Hcl | 39 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 38 | 37 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 37 | 13 |
| Doxepin Hcl | Doxepin Hcl | 36 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 36 | suppressed |
| Topiramate | Topiramate | 36 | 11 |
| Nitroglycerin | Nitroglycerin | 35 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 35 | suppressed |
| Colchicine | Colchicine | 34 | 12 |
| Sucralfate | Sucralfate | 34 | 11 |
| Azelastine Hcl | Azelastine Hcl | 33 | suppressed |
| Cephalexin | Cephalexin | 33 | 25 |
| Lidocaine | Lidocaine | 33 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 33 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 33 | 20 |
| Bumetanide | Bumetanide | 31 | suppressed |
| Mounjaro | Tirzepatide | 31 | suppressed |
| Repaglinide | Repaglinide | 31 | suppressed |
| Amoxicillin | Amoxicillin | 30 | 13 |
| Klor-Con M20 | Potassium Chloride | 30 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 29 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 27 | 11 |
| Spiriva Respimat | Tiotropium Bromide | 27 | suppressed |
| Entresto | Sacubitril/Valsartan | 26 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 26 | suppressed |
| Temazepam | Temazepam | 26 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 25 | suppressed |
| Estradiol | Estradiol | 25 | suppressed |
| Methocarbamol | Methocarbamol | 25 | suppressed |
| Olanzapine | Olanzapine | 25 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | suppressed |
| Digoxin | Digoxin | 24 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Nystatin | Nystatin | 24 | 15 |
| Levofloxacin | Levofloxacin | 23 | 19 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 17 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 22 | suppressed |
| Novolog Flexpen | Insulin Aspart | 22 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 21 | suppressed |
| Glipizide Er | Glipizide | 21 | suppressed |
| Lansoprazole | Lansoprazole | 21 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 21 | suppressed |
| Aripiprazole | Aripiprazole | 20 | suppressed |
| Carbamazepine Er | Carbamazepine | 20 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 20 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 20 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 20 | suppressed |
| Azithromycin | Azithromycin | 19 | 18 |
| Diazepam | Diazepam | 19 | suppressed |
| Indapamide | Indapamide | 19 | suppressed |
| Lactulose | Lactulose | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 18 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Metolazone | Metolazone | 17 | suppressed |
| Nexium | Esomeprazole Magnesium | 17 | suppressed |
| Risperidone | Risperidone | 17 | suppressed |
| Rybelsus | Semaglutide | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 15 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 15 | 15 |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 13 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 13 | suppressed |
| Creon | Lipase/Protease/Amylase | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Ingrezza | Valbenazine Tosylate | 13 | suppressed |
| Phenytoin | Phenytoin | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Rivastigmine | Rivastigmine | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Haloperidol | Haloperidol | 12 | suppressed |
| Mirabegron Er | Mirabegron | 12 | suppressed |
| Nabumetone | Nabumetone | 12 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 12 | suppressed |
| Ursodiol | Ursodiol | 12 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Oxycontin | Oxycodone Hcl | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $266.76 · 6 records | Phathom Pharmaceuticals, Inc. | MOUNJARO, NURTEC ODT, Ozempic, PAXLOVID, VOQUEZNA | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error